AzurRx BioPharma
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of AzurRx BioPharma generated cash of -$11,221,538, which is more than the previous year. Cash used in financing activities reached the amount of $17,046,121 last year. Net change in cash is therefore $5,886,345.
Cash Flow
| 2015 | -4.51M | -24.38K | 5.02M |
|---|---|---|---|
| 2016 | -4.53M | -12.35K | 5.74M |
| 2017 | -7.18M | -32.16K | 6.01M |
| 2018 | -10.86M | -305.47K | 11.71M |
| 2019 | -14.03M | -24.09K | 13.14M |
| 2020 | -11.22M | 87.35K | 17.04M |
AZRX Cash Flow Statement (2015 – 2020)
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 175.79K | 1.11M | 573.47K | 1.77M | 581.66K | 94.83K |
Operating activities | ||||||
Net income | -32.67T | -15.17M | -13.53M | -11.09M | -14.59M | -5.93M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 37.79K | 1.02M | 798.44K | 753.99K | 734.5K | 733.59K |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 2.08M | 0 | 0 | 0 | 0 | 0 |
Inventories | -455.89K | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -750.02K | -420.78K | 741.62K | 0 | 0 | 0 |
Cash generated by operating activities | -11.22M | -14.03M | -10.86M | -7.18M | -4.53M | -4.51M |
Investing activities | ||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -4.16K | -24.09K | -55.47K | -32.16K | -12.35K | -24.38K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 87.35K | -24.09K | -305.47K | -32.16K | -12.35K | -24.38K |
Financing activities | ||||||
Common Stock Issued | 988.34K | 9.47M | 0 | 5.00M | 5.28M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 16.31M | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -475K | 0 | -476.88K | 0 | -439.59K | 0 |
Cash used in financing activities | 17.04M | 13.14M | 11.71M | 6.01M | 5.74M | 5.02M |
Net Change In Cash | 5.88M | -938.54K | 540.87K | -1.20M | 1.19M | 486.83K |
Cash at end of period | 6.06M | 175.79K | 1.11M | 573.47K | 1.77M | 581.66K |
| Data source | Data source | Data source | Data source | Data source |